Stocks You Wish You'd Bought

Recs

5

It's no surprise that international stocks have gained popularity with investors over the past few years. They've generated absolutely amazing growth.

For the past six years in a row, the Vanguard Total International Stock Market Index outpaced the Vanguard Total Stock Market Index. The latter tracks just the broad U.S. market, including top holdings in Cisco Systems and General Electric.

Even though foreign markets probably won't outperform U.S. markets every year, international stocks are undeniably worth your time to research. And thanks to American depositary receipts (ADRs), U.S. investors have more opportunities than ever to trade foreign securities on domestic exchanges.

This month's best performances
Foreign companies that participate in an ADR program must file reports in accordance with U.S. regulations, but their corporate cultures and business decisions can seem unorthodox to American investors.

To help us understand this month's top-performing ADRs, we'll tap the expertise of the more than 110,000 members participating in Motley Fool CAPS, the Fool's free investing community. Here are the top four performers over the past month among ADRs, along with their ratings from the CAPS community.

Company

Country

1-Month
% Change

CAPS Rating
(out of 5)

Randgold Resources (Nasdaq: GOLD)

Channel Islands

27.6%

***

WuXiPharmaTech (NYSE: WX)

China

25.1%

*****

The9 Limited (Nasdaq: NCTY)

China

19.7%

*****

Xinhua Finance Media (Nasdaq: XFML)

China

18.1%

**

Data provided by Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS as of July 21; screen excludes companies with market caps of less than $100 million.

Remember, I chose these stocks as jumping-off points for further research, not as formal recommendations. That said, checking out stocks with CAPS's four- and five-star ratings is an effective tool for investors.

Why they rallied
Randgold: As the saying goes, "A rising tide lifts all boats," and a recent rebound in gold prices certainly hasn't hurt Randgold. Over the past month, the gold-tracking SPDR Gold Shares (NYSE: GLD) ETF has gained 7%. Despite its recent performance, CAPS members are a tad skeptical of Rangold's prospects and still rate it a mediocre three stars.

WuXi: The Chinese pharmaceutical research and development outsourcer won a big contract from U.S.-based Covance (NYSE: CVD) providing the stock with a much-needed boost.  Over on CAPS, 81 of the 85 All-Star members who have rated the stock think it will outperform the S&P 500 going forward.  

The9 Limited: Online gaming, specifically massively multiplayer online role-playing games (MMORPGs) such as Activision Blizzard's (Nasdaq: ATVID) wildly popular World of Warcraft, are not only huge in the U.S., but in China as well. The9 is licensed to distribute World of Warcraft and similar online games in China. Earlier this month, The9 entered into a joint venture with Korean game developer T3 Entertainment which provided some encouraging news to investors in the beaten-down stock.

Xinhua Finance Media: It's been a rough go for Xinhua Finance since its IPO; the stock presently sits some 80% off its March 2007 offer price. News of fresh insider buying at depressed prices back in late June briefly provided some confidence to investors. CAPS members still aren't convinced, and XF retains its lowly two-star rating.

What do you think?
Read what other investors have to say about these stocks, and then make your voice heard on Motley Fool CAPS. It's 100% free, so sign up today!

“Make Big Money With Options” Motley Fool CFO Ollen Douglass recently made over $100,000 buying options on 7 well known stocks. Now we’re committed to turning his small fortune into a massive one! And we want you to join us! Enter your email address to hear more:

Activision Blizzard is a Motley Fool Stock Advisor pick. Try any of our Foolish newsletters free for 30 days.

Todd Wenning puts his shoes on one at a time, just like everyone else. He does not own shares of any company mentioned. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 690236, ~/Articles/ArticleHandler.aspx, 12/1/2009 11:49:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
The Public Health-Care Plan's Problem

Related Tickers

2/27/2009 3:58 PM
XFML $0.44 Down +0.00 +0.00%
Xinhua Finance Med… CAPS Rating: **
GOLD $88.26 Up +3.52 +4.15%
Randgold Resources… CAPS Rating: **
CVD $54.26 Up +1.15 +2.17%
Covance, Inc. CAPS Rating: ****
GLD $117.47 Up +1.83 +1.58%
SPDR Gold Trust (E… CAPS Rating: ***
WX $17.19 Down -0.24 -1.38%
WuXi PharmaTech (C… CAPS Rating: ****
NCTY $7.58 Up +0.03 +0.40%
The9 Limited (ADR) CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

PDUFA: The Prescription Drug User Fee Act (PDUFA) is a law enacted by Congress that gives powers to the FDA.

Want to learn more or edit this definition?
Click here to read more!